Announcements Trials
Browse Landscape

Phase

Phase 2 28Phase NA 4Phase 1/2 4Phase 1 4Phase 3 3

Status

Unknown 2Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 4

Conditions

Carcinoma, Non-Small-Cell Lung 8Advanced Solid Tumor 7Squamous Cell Carcinoma of Head and Neck 5Neoplasm Metastasis 5Colorectal Neoplasms 5Stomach Neoplasms 4Melanoma 4Carcinoma, Hepatocellular 4Solid Tumor 3Solid Tumors 2Lymphoma 2Head and Neck Neoplasms 2Esophageal Squamous Cell Carcinoma 2Carcinoma, Renal Cell 2Advanced Solid Tumors 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Testicular Germ Cell Tumor 1Skin Neoplasms 1Simpson-Golabi-Behmel syndrome 1Sarcoma 1Recurrence 1Rectal Neoplasms 1Pancreatic Neoplasms 1Pancreatic Ductal Adenocarcinoma 1Neuroendocrine Tumors 1Neoplasms 1Nasopharyngeal Carcinoma 1Muscle Invasive Bladder Cancer 1

Interventions

Sorafenib 37Nivolumab 21pembrolizumab 18Bevacizumab 12Cyclophosphamide 10durvalumab 9fludarabine 8atezolizumab 8Magnetic Resonance Spectroscopy 8lenvatinib 7Radiosurgery 7Ipilimumab 7Radiotherapy 6Irinotecan 6Oxaliplatin 5Leucovorin 5tremelimumab 4toripalimab 4tislelizumab 4sintilimab 4cabozantinib 4budigalimab 4Specimen Handling 4Sirolimus 4Interleukin-2 4Fluorouracil 4Doxorubicin 4Capecitabine 4130-nm albumin-bound paclitaxel 4spartalizumab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1 × Carcinoma, Hepatocellular × tislelizumab × Clear all
NCT06427941 2026-05-14

A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors

BeOne Medicines

Phase 1 Recruiting
392 enrolled
Gastrointestinal

Simpson-Golabi-Behmel syndrome, Carcinoma, Hepatocellular

NCT07077369 2025-07-22

WGc-0201 Plus Tislelizumab in HCC With High Risk of Recurrence and Metastasis After Radical Therapy

West China Hospital

Phase 1 Not yet recruiting
10 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT05533892 2023-12-19

CCGLC-007

Tongji Hospital

Phase 1 Unknown
30 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT05675462 2023-03-06

Oncolytic Virotherapy Plus PD-1 Inhibitor and Lenvatinib as Second-line or Later Therapy in Patients With Advanced Hepatocellular Carcinoma

Fudan University

Phase 1 Unknown
25 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡